Table 1:

Summary of Treatment Options for Castration-Resistant Prostate Carcinoma

Drug	Mechanism of Action	Overall Survival Benefit	Selected side effects	Approved Indications
Abiraterone	Androgen synthesis inhibitor	34.7 mo vs 30.3 mo with Pred in chemo naïve. 15.8 mo vs 11.2 mo with Pred in pts with prior docetaxel	Hypertension, Hypokalemia, Edema	Treatment of docetaxel-naïve and docetaxel-pretreated metastatic CRPC
Enzalutamide	Androgen receptor blocker	35.3 mo vs 31.3 mo in PBC arm in chemo naïve and 18.4 mo vs 13.6 mo in pts with prior docetaxel	Seizures, Back pain	Treatment of docetaxel-naïve and docetaxel-pretreated metastatic CRPC
Docetaxel	Microtubule inhibitor	18.9 mo vs 16.5 months with mitoxantrone	Neutropenia, neuropathy, stomatitis, tear duct sclerosis	First-line chemotherapy treatment of metastatic CRPC
Cabazitaxel	Microtubule inhibitor	15.1 mo versus 12.7 mo with mitoxantrone	Neutropenia, Diarrhea	Second-line chemotherapy for mCRPC after progression on docetaxel
Radium-223	Bone-seeking radioactive isotope	14.9 months versus 11.2 months with placebo	Myelosuppression, Diarrhea	Symptomatic bony disease with no visceral metastases
Sipuleucel-T	Patient-derived antigen-presenting cell vaccine	25.8 mo vs 21.7 mo versus placebo	Mild acute-phase reactions (fevers, chills)	Minimally or asymptomatic metastatic CRPC

Abbreviations: CRPC: Castration-Resistant Prostate Cancer, Mo: Months, PFS: Progression-Free Survival, OS: Overall Survival, Chemo: Chemotherapy, Pred: Prednisone, PBO: Placebo, pts: patients